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In late 2015-early 2016, a public e-petition prompted a House of Commons Select 
Committee enquiry and subsequent parliamentary debate into brain tumour research, 
highlighting the devastating impact that brain tumours have on patients and their families. 
Two key areas of concern were the potential impact of diagnostic delays on survival and 
quality of life for patients and their families, and the low priority given to brain tumour 
research by government and funders.1 
The prognosis for primary brain tumours remains poor; only 40% of people diagnosed with 
malignant brain tumours live for more than a year, and less than 20% for more than five 
years.2 Although patients with brain/CNS tumours lose more than 20 years of life on 
average, the highest among commoner cancer types,2 improving early diagnosis of brain 
tumours has long been perceived as unfeasible due to poor symptom specificity. However, 
during the last decade the median total diagnostic interval for paediatric brain tumours has 
halved (101 days in 2006 to 47 days in 2013), probably due to a range of factors including 
the publication of NICE guideline CG27 on referral for suspected cancer in June 2005, the 
two-week urgent referral pathway, and the UK-wide HeadSmart public and professional 
awareness campaign, focusing on the symptoms and signs of brain tumours in children and 
young people.3,4 Learning from this success, can we now improve time to diagnosis for adult 
primary brain tumours?  
 
CURRENT EXPERIENCE OF ADULTS DIAGNOSED WITH PRIMARY BRAIN TUMOURS 
Multiple primary care consultations occur commonly among adults subsequently diagnosed 
with primary brain tumours. Evaluation of the National Cancer Patient Experience Surveys 
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showed that 39% of brain/CNS cancer patients had three or more pre-referral consultations 
with a GP compared to an average of 25% for all cancers; furthermore, a third reported 
declining health while waiting to see a hospital doctor compared with a fifth of patients 
across all tumour groups.5 National primary care audit data analyses reported similar 
findings, and also demonstrated longer diagnostic intervals related to multiple primary care 
consultations: a quarter of brain cancer patients with three to four, and five or more 
consultations experienced intervals longer than 62 and 166 days respectively.6  
Emergency presentations are a common route for diagnosis of adult brain tumours, with 
61% presenting through this route between 2006 and 2013. This figure was second only to 
acute lymphoblastic leukaemia. This matters, as emergency presentations are associated 
with a significantly lower one-year relative survival compared to other non-emergency 
routes to diagnosis,7 and emergency brain surgery is associated with an increased risk of 
morbidity and mortality. Advanced disease also comes with a greater risk of acquired 
neurological disability due to tumour-related brain injury. 
 
BARRIERS TO DIAGNOSING ADULT PRIMARY BRAIN TUMOURS 
The 2015 NICE guidelines for recognition and referral of suspected cancer lowered the 
threshold for GPs to refer suspected adult brain and CNS cancers for urgent investigation 
(CG12), and some areas also now have direct access brain MRI available.  In spite of these 
developments, diagnosing brain tumours is challenging for GPs, as the vast majority of 
patients with neurological symptoms are diagnosed with benign disease and the probability 
of having a patient with a brain tumour is very low.  The positive predictive values (PPVs) of 
either single symptoms (such as headaches, weakness, confusion, memory loss, and visual 
or motor disturbance) or symptom combinations for brain/CNS cancer are all low (less than 
1%), with the exception of new-onset or first seizure (although it is worth noting that 
current NICE guidance for investigation of a first seizure (CG137) does not routinely 
recommend early imaging, thus potentially delaying diagnosis of tumours presenting 
through this route).8  Currently, we understand little about why patients present as 
emergencies or make several visits to the GP before referral, and the presentation, 
assessment and diagnosis of brain tumours is not well described. Evidence is lacking about 
how adult patients with primary brain tumours detect and assess their symptoms, decide to 
seek help, and their experiences of pathways to diagnosis. For other cancer sites a number 
of sociodemographic factors (such as age, gender, living alone, educational level, health 
literacy), clinical factors (such as presenting symptom/s and co-morbidities), and health-
related behaviours (such as self-medication), have been associated with time from first 
symptom detection to diagnosis (known as the total diagnostic interval). It is likely that 
these factors also affect presentation with a brain tumour. Among the few qualitative 
studies undertaken worldwide which explore the pathway to diagnosis for brain tumour 
patients, one set in Sweden and one in the UK have both shown that subtle or non-specific 
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symptoms or a personality change due to the developing tumour, may delay help-seeking. 
Furthermore, patients may be unaware of, or lack insight into, some symptoms (although 
these may be observed by family members, friends or work colleagues), and thus do not 
report them.9,10 
 
HOW CAN WE EXPEDITE DIAGNOSIS OF ADULT PRIMARY BRAIN TUMOURS? 
There is an urgent need for rigorous multi-methods research in order to better understand 
what may impede and facilitate the diagnosis of primary brain tumours. A robust theoretical 
framework, with a focus on understanding factors affecting patients’ symptom appraisal 
and help-seeking behaviour, has been successfully applied to other cancers (including 
colorectal cancer and melanoma),11 and could similarly illuminate patient pathways to 
presentation and diagnosis with brain tumours in order to inform awareness campaigns. 
Once patients present to primary care, GPs need risk assessment tools to triage and direct 
appropriate management including rapid access to CT scans and to neurological services. 
Diagnostic capacity will need to be increased to meet demand, and alternative models of 
assessment could draw on those being developed for childhood cancer. Biomarkers are 
likely to provide the most effective means to expediting diagnosis but there is currently a 
dearth of candidates.  Pharmacists and opticians may also be the patient’s first point of 
contact with healthcare, and need close involvement in revised care pathways. Given the 
high proportion of brain tumours that are diagnosed as an emergency, there is a particular 
need to better understand the mechanisms leading to emergency diagnosis. For example, 
we need to distinguish between emergency diagnosis at first presentation versus 
emergency diagnosis in patients who have sought help previously, and the underlying 
reasons for these scenarios, including whether emergency presentation was potentially 
avoidable. 
Could more timely diagnosis improve survival and quality of life? The James Lind Alliance 
Priority Setting Partnership (JLA PSP) in Neuro-Oncology has identified this among their ‘Top 
10’ priorities for future research.12  In a recent Delphi study on the effects of expedited 
cancer diagnosis, clinical expert participants judged that brain tumour patients would 
experience benefits in morbidity, including provision of symptom relief and possible 
improvement in psychological wellbeing, despite less mortality benefit compared to other 
cancers.13 Survival rates differ markedly for different tumour types and grades, and a key 
challenge associated with determining the impact of early diagnosis is tumour 
heterogeneity and resulting low patient numbers for each individual tumour type. 
Nevertheless, research that illuminates the barriers and facilitators to early diagnosis could 
help reduce time to diagnosis for adult primary brain tumours, and potentially alleviate the 
devastating impact on patients and their families. This could be achieved through informing 
a campaign along the lines of HeadSmart, focused on adults, and combining high quality, 
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evidence-based guidance for primary care clinicians with public awareness-raising regarding 
the range of symptoms that might be suspicious of a brain tumour.  
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